IP Library Granted Patent US 8,491,852
Granted Patent B2
US 8,491,852 · App. 11/914,884 · Granted Jul 23, 2013

Marker of wound infection

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,491,852
App. No.
11/914,884
Granted
Jul 23, 2013
Kind
B2
Abstract

An indicator device adapted give a detectable signal when the antioxidant capacity of a sample of a mammalian wound fluid exceeds a predetermined minimum level which is characteristic of an infected wound. Also provided system for use in the diagnosis and treatment of wounds comprising the inventive diagnostic device and a wound dressing comprising at least one antimicrobial agent for selective application to infected wounds. Also provided are methods of diagnosis and treatment by means of the inventive device and system.

Claims (14)

1. A system for use in the diagnosis and treatment of wounds comprising a diagnostic device, the diagnostic device comprising an indicator device adapted to give a detectable signal when the antioxidant capacity of a sample of a mammalian wound fluid exceeds a predetermined minimum level which is characteristic of an infection, the indicator device comprising a housing containing one or more reagents, the housing having at least one inlet provided therein for introduction of the sample, wherein the indicator device comprises a source of at least one reactive oxygen species and an indicator molecule that reacts with the reactive oxygen species to produce a detectable change, and a wound dressing comprising at least one antimicrobial agent, the wound dressing to be applied to the wound when the measured total antioxidant capacity is indicative of an infected wound.

2. The system for use in the diagnosis and treatment of wounds of claim 1 comprising a diagnostic device, wherein the indicator device comprises a redox indicator molecule selected from the group consisting of Cytochrome C, 1,10-phenanthroline iron salt, diphenylamine sulfonic acid, triphenylmethane dyes, starch-iodine, diphenylpicryihydrazyl (DPPH) and 2,2′-azino-di(3-ethylbenzthiazoline sulfonate) (ABTS).

3. The system for use in the diagnosis and treatment of wounds of claim 1 comprising a diagnostic device, wherein the indicator device comprises an electrochemical sensor.

4. The system for use in the diagnosis and treatment of wounds of claim 1 comprising a diagnostic device, wherein the indicator device comprises a wound dressing, dipstick or swab.

5. The system for use in the diagnosis and treatment of wounds of claim 1 comprising a diagnostic device, which is a lateral flow diagnostic device.

6. The system for use in the diagnosis and treatment of wounds of claim 1 comprising a diagnostic device, wherein the indicator device is adapted to detect at least one further analyte in addition to the total antioxidant capacity of the sample.

7. The system for use in the diagnosis and treatment of wounds of claim 6 comprising a diagnostic device, wherein the at least one further analyte comprises total protein content of the sample.

8. A system for use in the diagnosis and treatment of wounds comprising a diagnostic device, the diagnostic device comprising an indicator device adapted to give a detectable signal when the antioxidant capacity of a sample of a mammalian wound fluid exceeds a predetermined minimum level which is characteristic of an infection, the indicator device comprising a housing containing one or more reagents, the housing having at least one inlet provided therein for introduction of the sample, wherein the indicator device comprises a source of at least one reactive oxygen species and an indicator molecule that reacts with the reactive oxygen species to produce a detectable change, and a wound dressing to be applied to the wound when the measured total antioxidant capacity is indicative of a non-infected wound.

9. The system for use in the diagnosis and treatment of wounds of claim 8 comprising a diagnostic device, wherein the device comprises a redox indicator molecule selected from the group consisting of Cytochrome C, 1,10-phenanthroline iron salt, diphenylamine sulfonic acid, triphenylmethane dyes, starch-iodine, diphenylpicryihydrazyl (DPPH) and 2,2′-azino-di(3-ethylbenzthiazoline sulfonate) (ABTS).

10. The system for use in the diagnosis and treatment of wounds of claim 8 comprising a diagnostic device, wherein the device comprises an electrochemical sensor.

11. The system for use in the diagnosis and treatment of wounds of claim 8 comprising a diagnostic device, wherein the device comprises a wound dressing, dipstick or swab.

12. The system for use in the diagnosis and treatment of wounds of claim 8 comprising a diagnostic device, which is a lateral flow diagnostic device.

13. The system for use in the diagnosis and treatment of wounds of claim 8 comprising a diagnostic device, wherein the device is adapted to detect at least one further analyte in addition to the total antioxidant capacity of the sample.

14. The system for use in the diagnosis and treatment of wounds of claim 13 comprising a diagnostic device, wherein the at least one further analyte comprises total protein content of the sample.

Assignments (9)
RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Feb 6, 2017
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: KCI LICENSING, INC., AS GRANTOR; TECHNIMOTION, LLC, A DELAWARE LIMITED LIABILITY COMPANY, AS GRANTOR; SYSTAGENIX WOUND MANAGEMENT (US), INC., A DELAWARE CORPORATION, AS GRANTOR
Reel/Frame 041395/0044 →
CORRECTIVE ASSIGNMENT TO CORRECT THE NAME OF RECEIVING PARTY PREVIOUSLY RECORDED AT REEL: 033699 FRAME: 0204. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Sep 18, 2014
From: SYSTAGENIX WOUND MANAGEMENT (US), INC.
To: WOUNDCHEK LABORATORIES (US), INC.
Reel/Frame 033773/0781 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 9, 2014
From: SYSTAGENIX WOUND MANAGEMENT (US), INC.
To: WOUNDCHECK LABORATORIES (US), INC.
Reel/Frame 033699/0204 →
SECURITY AGREEMENT Recorded Oct 29, 2013
From: SYSTAGENIX WOUND MANAGEMENT (US), INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 031508/0011 →
RELEASE OF SECURITY INTEREST Recorded Oct 28, 2013
From: J.P. MORGAN EUROPE LIMITED
To: SYSTAGENIX WOUND MANAGEMENT (US), INC.
Reel/Frame 031506/0186 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 21, 2010
From: ETHICON, INC.; JOHNSON & JOHNSON MEDICAL LIMITED
To: SYSTAGENIX WOUND MANAGEMENT IP CO. B.V.
Reel/Frame 024563/0344 →
SECURITY AGREEMENT Recorded Jan 30, 2009
From: SYSTAGENIX WOUND MANAGEMENT (US), INC.
To: J.P. MORGAN EUROPE LIMITED
Reel/Frame 022177/0037 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 8, 2009
From: ETHICON, INC.; JOHNSON & JOHNSON MEDICAL LIMITED
To: SYSTAGENIX WOUND MANAGEMENT (US), INC.
Reel/Frame 022071/0762 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 22, 2008
From: CULLEN, BREDA MARY; CLARK, RACHAEL LOUISE; STEPHENS, PHILIP; MOSELEY, RYAN
To: ETHICON, INC.
Reel/Frame 021434/0823 →